Printable Handouts

PDF

Navigable Slide Index

1. Activation of PTK receptors in solid human tumors
2. Human kinome
3. Human tyrosine kinases
4. Human PTK receptors (RTKs)
5. The role of TKs in cancer
6. Receptor tyrosine kinases altered in solid tumors
7. Mechanism of activation of RTKs
8. Ligand dependent activation of RTK (1)
9. Ligand dependent activation of RTK (2)
10. Ligand dependent activation of RTK (3)
11. Ligand dependent activation of RTK (4)
12. Pathological activation of RTKs
13. Autocrine loop
14. Autocrine loop in solid human tumors
15. Pathological activation by autocrine loop (1)
16. Pathological activation by autocrine loop (2)
17. Pathological activation by autocrine loop (3)
18. Pathological activation by autocrine loop (4)
19. Pathological activation by autocrine loop (5)
20. Pathological activation by autocrine loop (6)
21. Autocrine loop in solid human tumors - DP
22. Dermatofibrosarcoma protuberans DP
23. Characterization of PD
24. Gene fusion in DP
25. PDGF break point are upstream exon 2
26. Transforming the fusion gene
27. Growth inhibitory effect of STI571
28. In vivo effects of Gleevec on tumor growth
29. Gene amplification
30. Gene amplification - examples
31. Pathological activation by gene amplification (1)
32. Pathological activation by gene amplification (2)
33. Pathological activation by gene amplification (3)
34. Gene amplification - Her2
35. Her2 expression in breast cancer
36. Effect of histological grade on disease free survival
37. Mutation
38. Mutation - example
39. Pathological activation by mutation (1)
40. Pathological activation by mutation (2)
41. Pathological activation by mutation (3)
42. Pathological activation by mutation (4)
43. Mutation - EGFR and Her2
44. EGFR mutations in lung cancer
45. Mutations in the TK domain
46. Intragenic ERBB2 kinase mutations in tumors
47. Pathological activation by mutation
48. Mutation - Ret
49. Pathological condition associated to Ret mutations
50. Ret germline activating mutations
51. Disulfide bond-mediated RET dimerization
52. Dimerization and tyrosine phosphorylation of Ret
53. Gene rearrangement
54. Gene rearrangement - examples
55. Pathological activation by gene rearrangement
56. Gene rearrangement - TRK and Ret
57. Ret and TRK oncogenes in PTC
58. Inv (10) (q11.2q21)
59. Ret and TRK thyroid oncogenes
60. Genes activating Ret and TRK
61. Ret and TRK oncoproteins display TK activity
62. Ret and NTRK1 in human diseases
63. Tyrosine kinase as therapeutic targets
64. Gleevec as a paradigm of Rtk targeted therapy
65. Gleevec, dermatofibrosarcoma P, PDGFR
66. Gleevec, Gist, Kit: a case report
67. Biochemical experiments
68. DNA sequencing
69. In vitro experiments
70. Gefitinib, NSCLC, EGFR
71. EGFR TK mutations
72. Gefitinib, colorectal cancer, EGFR
73. Genetic profile of metastatic colorectal cancer
74. EGFR gene copy number and anti EGFR response
75. A new paradogm
76. High throughput sequencing
77. A screen of the complete PK gene family
78. Cancer genetics - conclusionj

Topics Covered

• The human kinome
• Role of tyrosine kinases in cancer
• Mechanisms of activation of RTKs in physiological and pathological conditions
• Autocrine Loop
• The dermatofibrosarcoma protuberans model
• Gene Amplification
• the breast cancer model
• Mutation
• The EGFR and lung cancer model
• The Ret and multiple endocrine type 2 syndrom model
• Gene rearrangment
• The RET and TRK in papillary thyroid carcinoma model
• Thyrosine Kinases and therapeutic targets
• The Gleevec paradigm
• The EGFR inhibitors a new paradigm

Links

Series:

• Signal Transduction via Protein Tyrosine Kinase Receptors

Categories:

• Biochemistry
• Cancer
• Cell Biology

Therapeutic Areas:

• Oncology

Talk Citation

Pierotti, M. (2007, October 1). Activation of PTK receptors in solid human tumors [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/OXOV2356.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on May 31, 2018

Financial Disclosures

• Dr. Marco Pierotti has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.